Tarantula venom-based MD therapy to be advanced by UB scientists’ biotech company

BUFFALO, N.Y. — University at Buffalo biophysicists have found a protein in tarantula venom that shows promise as a potential therapy for muscular dystrophy (MD). They have formed a start-up biotech company in Buffalo — Rose Pharmaceuticals — to advance the drug to clinical trials.

Fredrick Sachs, PhD, professor of physiology and biophysics at the University at Buffalo, and colleagues in his laboratory, discovered the peptide, called GsMTx4.

Full story:

http://www.genengnews.com/news/bnitem.aspx?name=72104712

Tags: ,

About admin